

Date: Thursday, 20th May 2021  
Our Ref: MB/SS FOI 4723

Sid Watkins Building  
Lower Lane  
Fazakerley  
Liverpool L9 7BB  
Tel: 01515253611  
Fax: 01515295500  
Direct Line: 01515563038

**Re: Freedom of Information Request FOI 4723**

We are writing in response to your request submitted under the Freedom of Information Act, received in this office on 30th April 2021.

Your request was as follows:

I am analysing the treatment of neurology patients within secondary care. Could you please answer the following three questions:

1. How many patients have been treated with the following drugs (for any disease) in the past 6 months:

- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaferon (interferon beta-1b)
- Brabio (glatiramer acetate)
- Copaxone (glatiramer acetate)
- Extavia (beta interferon-1b)
- Fampyra (fampridine)
- Gilenya (fingolimod)

- Lemtrada (alemtuzumab)
- Mavenclad (cladribine)
- Mayzent (siponimod)
- Ocrevus (ocrelizumab)
- Plegridy (peginterferon beta-1a)
- Rebif (beta interferon-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
- Zeposia (ozanimod)

Aubagio (teriflunomide) - 50

Avonex (interferon beta-1a) - 17

Betaferon (interferon beta-1b) - 3

Brabio (glatiramer acetate) - 0

Copaxone (glatiramer acetate) - 282

Extavia (beta interferon-1b) - 1

Fampyra (fampridine) - 3

Gilenya (fingolimod) - 140

Lemtrada (alemtuzumab) - 1

Mavenclad (cladribine) - 2

Mayzent (siponimod) - 0

Ocrevus (ocrelizumab) - 42

Plegridy (peginterferon beta-1a) - 31

Rebif (beta interferon-1a) - 78

Tecfidera (dimethyl fumarate) - 280



Tysabri (natalizumab) - 104  
Zeposia (ozanimod) - 0

Q2. How many patients have been treated with the following drugs in the past 4 months:

- Ajovy (fremanezumab) - any disease
- Aimovig (erenumab) - any disease
- Emgality (galcanezumab) - any disease
- Botulinum Toxin (i.e. Botox, Dysport, Xeomin) - migraine ONLY

- Ajovy (fremanezumab) - any disease - 132
- Aimovig (erenumab) - any disease - 18
- Emgality (galcanezumab) - any disease - 3

Please note we are not able to provide Botox information as this information is not available through pharmacy as we do not get information about the indication.

Q3. How many patients have been treated in the past 4 months for the following conditions:

- Chronic migraine (15+ headache days per month)
- Episodic migraine (4-14 headache days per month)
- Primary progressive multiple sclerosis (PPMS)
- Secondary progressive multiple sclerosis (SPMS)

- Chronic migraine (15+ headache days per month) 887
- Episodic migraine (4-14 headache days per month) We don't code episodic migraines therefore this information

cannot be provided however overall 1079 patients have a migraine code, 887 were chronic.

- Primary progressive multiple sclerosis (PPMS) 103
- Secondary progressive multiple sclerosis (SPMS) 186

Please see our response above in [blue](#).

#### **Re-Use of Public Sector Information**

All information supplied by the Trust in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2005, Statutory Instrument 2005 No. 1515 which came into effect on 1st July 2005.

Under the terms of the Regulations, the Trust will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however the Trust reserves the right, in certain circumstances, to charge a fee for the re-use of some information which it deems to be of commercial value.

Further information can be found at [www.opsi.gov.uk](http://www.opsi.gov.uk) where a sample license terms and fees can be found with guidance on copyright and publishing notes and a Guide to Best Practice and regulated advice and case studies, at [www.opsi.gov.uk/advice/psi-regulations/index.htm](http://www.opsi.gov.uk/advice/psi-regulations/index.htm)

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to the Freedom of Information Office at the address above.

**Please remember to quote the reference number, FOI 4723 in any future communications.**

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioners Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

Yours sincerely

*Mike Burns*

**Mr. Mike Burns, Executive Lead for Freedom of Information**